Onco Therapies Limited (OTL), the wholly-owned oncology subsidiary of Strides, has received the UK's approval for Oxaliplatin injections in strengths of 5 mg per 10 ml, 5 mg per 20 ml and 5 mg per 40 ml, Strides Arcolab said in a statement.
"The current approval is from UK and approval for the rest of the European countries is expected shortly," it added.